Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment

Spanish Startup Aims to Develop Novel Genomic Tests to Guide Breast Cancer Treatment

Oct 12, 2020
|
Justin Petrone
Premium

NEW YORK – Reveal Genomics is a newly formed company with a lofty goal: to translate years of experience in the cancer clinic into genomic tests that can be used to guide treatment decisions. Established last month in Barcelona, Reveal plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

What's Popular?

In Cancer

  1. Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

  2. Adaptive Biotechnologies, LabCorp Expand Collaboration

  3. AnchorDx Closes $40M Series C Financing Round

  4. AMP Survey Finds Significant Decline in Molecular Cancer Testing Due to COVID-19 Pandemic

  5. NeoGenomics Q4 Revenue Grows 18 Percent, CEO to Retire

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.